These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1108 related articles for article (PubMed ID: 508607)

  • 1. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
    Helander I; Nordman E; Häkkinen IP; Toivanen A
    Br J Dermatol; 1979 Oct; 101(4):421-7. PubMed ID: 508607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological changes in cancer patients receiving BCG.
    Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
    Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.
    Golub SH; Forsythe AB; Morton DL
    Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 16. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 18. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 20. Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.
    Lui VK; Karpuchas J; Dent PB; McCulloch PB; Blajchman MA
    Br J Cancer; 1975 Sep; 32(3):323-30. PubMed ID: 1233077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.